Medtech firm 'set to scale' after £1.2 million backing
A medical technology firm says it is feeling fit for growth after securing £1.2 million support.
ClotProtect has been backed by Innovate UK and Lifted Ventures Angel Network investment.
The Leeds-based operator says the cash will provide a “platform to scale faster and bring technology to more patients… by progressing regulatory and clinical pathways”.
Co-founded by Professor Helen Philippou, Dr Richard Foster and Ned Wakeman, the University of Leeds spin-out company is known for treatment focused on reducing blood clot risks.
The firm was supported by Lifted Ventures’ Elevate Her accelerator programme, backed by Leeds City Council, with bosses receiving ongoing mentorship from Lifted Ventures’ co-founder Jordan Dargue.
Professor Philippou said: “Taking part in the Elevate Her accelerator was a turning point.
“The support, mentorship and belief from the Lifted team, particularly from Jordan, has been instrumental in helping us secure Innovate UK funding and close this £1.2 million round.”
Jordan added: “Helen is an exceptional founder tackling a critical healthcare challenge.
“Supporting her through Elevate Her – and continuing to mentor her as she built momentum towards a £1.2 million round – is exactly what Lifted Ventures is about.”
Lifted Ventures is supported by British Business Bank.
Looking to promote your product/service to SME businesses in your region? Find out how Bdaily can help →
Enjoy the read? Get Bdaily delivered.
Sign up to receive our popular Yorkshire & The Humber morning email for free.
Navigating the messy middle of business growth
We must make it easier to hire young people
Why community-based care is key to NHS' future
Culture, confidence and creativity in the North East
Putting in the groundwork to boost skills
£100,000 milestone drives forward STEM work
Restoring confidence for the economic road ahead
Ready to scale? Buy-and-build offers opportunity
When will our regional economy grow?
Creating a thriving North East construction sector
Why investors are still backing the North East
Time to stop risking Britain’s family businesses